Santos-Oliveira Joana, Torrão Luís, Torres-Costa Sónia, Silva Marta, Pedrosa Ana Catarina, Araújo Joana, Figueira Luís, Oliveira-Ferreira Cláudia
Ophthalmology Department, Centro Hospitalar Universitário de São João, Porto, Portugal.
Surgery and Physiology Department, Faculty of Medicine of the University of Porto, Porto, Portugal.
Case Rep Ophthalmol. 2025 Feb 12;16(1):194-201. doi: 10.1159/000543908. eCollection 2025 Jan-Dec.
Iatrogenic Cushing syndrome (ICS) can be caused by synthetic glucocorticoids administered through various routes. ICS caused by corticosteroid eye drops is an exceptional event, being more frequent in pediatric age. Herein, we describe a case of ICS associated with secondary adrenal insufficiency (SAI) caused by ocular topical corticosteroid treatment.
An 11-year-old girl was referred to our ocular inflammation department due to idiopathic, chronic, non-hypertensive, non-granulomatous bilateral anterior uveitis, treated with topical dexamethasone (eye drops, 1 mg/mL) for 1 year. During the past year, the child and her mother observed a gradual change in her physical appearance, particularly noting the development of a cushingoid facial appearance. Laboratory data revealed morning serum adrenocorticotropic hormone (ACTH) of 3.6 ng/L (7.2-63.3) and morning serum cortisol of 0.20 μg/dL (6.2-19.4). She was treated with methotrexate (15 mg/week, orally), and the topical corticosteroid regimen was progressively tapered and discontinued after 3 months. Nine months after the patient discontinued corticosteroid eye drops, her cushingoid face disappeared, and her laboratory data improved. Regarding the ophthalmological examination, the uveitis remained in remission with methotrexate, with no new episodes of intraocular inflammation.
Although rare, ophthalmologists must be aware of ICS and SAI and prioritize using the least potent corticosteroid for the shortest duration necessary. Additionally, clinicians should avoid abrupt cessation of long-term corticosteroid therapy as this can precipitate an adrenal crisis in the presence of adrenal insufficiency.
医源性库欣综合征(ICS)可由通过各种途径给予的合成糖皮质激素引起。由皮质类固醇眼药水引起的ICS是一种罕见情况,在儿童期更为常见。在此,我们描述一例由眼部局部使用皮质类固醇治疗引起的与继发性肾上腺功能不全(SAI)相关的ICS病例。
一名11岁女孩因特发性、慢性、非高血压、非肉芽肿性双侧前葡萄膜炎被转诊至我们的眼部炎症科,使用局部地塞米松(眼药水,1mg/mL)治疗1年。在过去一年中,患儿及其母亲观察到她的外貌逐渐改变,尤其注意到出现了库欣样面容。实验室数据显示清晨血清促肾上腺皮质激素(ACTH)为3.6ng/L(7.2 - 63.3),清晨血清皮质醇为0.20μg/dL(6.2 - 19.4)。她接受了甲氨蝶呤治疗(15mg/周,口服),局部皮质类固醇治疗方案逐渐减量,并在3个月后停药。患者停用皮质类固醇眼药水9个月后,库欣样面容消失,实验室数据有所改善。关于眼科检查,葡萄膜炎在甲氨蝶呤治疗下仍处于缓解期,未出现新的眼内炎症发作。
尽管罕见,但眼科医生必须了解ICS和SAI,并优先使用效力最低的皮质类固醇,且使用时间尽可能短。此外,临床医生应避免突然停止长期皮质类固醇治疗,因为在存在肾上腺功能不全的情况下,这可能引发肾上腺危象。